5/15/2025

Janusmed sex and gender

Janusmed sex and gender – haloperidol

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Haloperidol

Haloperidol

Class : C

Show all info

Print

Contact us

  1. de Leon J, Diaz FJ, Wedlund P, Josiassen RC, Cooper TB, Simpson GM. Haloperidol half-life after chronic dosing. J Clin Psychopharmacol. 2004;24(6):656-60.

  2. Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y et al. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J. 2003;3(2):105-13.

  3. McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS et al. Insight in first-episode psychosis. Psychol Med. 2006;36(10):1385-93.

  4. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-65.

  5. Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2005;5:3.

  6. Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002;110:27-37.

  7. Brettner F, Janitza S, Prüll K, Weninger E, Mansmann U, Küchenhoff H et al. Gender-Specific Differences in Low-Dose Haloperidol Response for Prevention of Postoperative Nausea and Vomiting: A Register-Based Cohort Study. PLoS One. 2016;11(1):e0146746.

  8. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;1(2):CD002852.

  9. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108:687-93.

  10. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.

  11. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008;23(3):201-9.

  12. Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther. 2003;29(2):125-47.

  13. Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry. 2006;21(4):251-8.

  14. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085-96.

  15. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28 Suppl 2(1):69-82.

  16. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol. 1999;9(4):239-45.

  17. Knol W, van Marum RJ, Jansen PA, Strengman E, Al Hadithy AF, Wilffert B et al. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach. J Clin Psychopharmacol. 2013;33(3):405-10.

  18. Jung DU, Conley RR, Kelly DL, Kim DW, Yoon SH, Jang JH et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67(9):1391-6.

  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]

  1. de Leon J, Diaz FJ, Wedlund P, Josiassen RC, Cooper TB, Simpson GM. Haloperidol half-life after chronic dosing. J Clin Psychopharmacol. 2004;24(6):656-60.
  2. Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y et al. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J. 2003;3(2):105-13.
  3. McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS et al. Insight in first-episode psychosis. Psychol Med. 2006;36(10):1385-93.
  4. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-65.
  5. Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2005;5:3.
  6. Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002;110:27-37.
  7. Brettner F, Janitza S, Prüll K, Weninger E, Mansmann U, Küchenhoff H et al. Gender-Specific Differences in Low-Dose Haloperidol Response for Prevention of Postoperative Nausea and Vomiting: A Register-Based Cohort Study. PLoS One. 2016;11(1):e0146746.
  8. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;1(2):CD002852.
  9. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108:687-93.
  10. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.
  11. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008;23(3):201-9.
  12. Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther. 2003;29(2):125-47.
  13. Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry. 2006;21(4):251-8.
  14. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085-96.
  15. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28 Suppl 2(1):69-82.
  16. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol. 1999;9(4):239-45.
  17. Knol W, van Marum RJ, Jansen PA, Strengman E, Al Hadithy AF, Wilffert B et al. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach. J Clin Psychopharmacol. 2013;33(3):405-10.
  18. Jung DU, Conley RR, Kelly DL, Kim DW, Yoon SH, Jang JH et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67(9):1391-6.
  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]